Sandie Gong and Devon Xin Xu, identified as 10% owners of Aditxt, Inc. (NASDAQ: ADTX), executed the sale of 100,000 shares of the biotechnology company's common stock on June 9, 2026. The transaction resulted in total proceeds of $6,880. This divestment represents a complete exit from the issuer, following the execution of multiple transactions with prices ranging from $0.068 to $0.074 per share. The weighted average price for the sold shares was recorded at $0.0688 per share.
The timing of this complete divestment is particularly notable given the current market performance of the stock. Aditxt shares are currently trading at $0.02, reflecting a substantial 76% decline over the preceding week. According to InvestingPro analysis, the company's overall financial health is rated as "WEAK." This assessment highlights two critical operational challenges: the company is rapidly depleting cash reserves and carries a significant debt burden. These factors are cited among 18 ProTips available to subscribers, underscoring the financial pressures facing the issuer.
The securities involved in this transaction were held directly within a brokerage account managed by Sandie Gong. Devon Xu, acting as the spouse of Sandie Gong, holds trading authorization over this account. Consequently, Xu may be deemed to have beneficially owned the securities subject to the transaction. The reporting persons acquired and disposed of all reported securities on the same trading day, ensuring a simultaneous execution of the buy and sell activities. Following the completion of this transaction, both Gong and Xu beneficially own no securities of Aditxt, Inc. As a result, they are no longer subject to Section 16 of the Securities Exchange Act of 1934 with respect to the issuer.
In parallel with the insider divestment, Aditxt Inc. has announced significant corporate developments involving its subsidiary, Ignite Proteomics LLC. The company confirmed that Ignite is set to go public through a special purpose acquisition company (SPAC) transaction. This deal values Ignite at approximately $150 million. Upon closing, Ignite will operate as an independent publicly traded company. To facilitate this transition, Aditxt has appointed Jeffrey M. Busch as interim CEO. Busch continues to serve as the CEO of Ignite Proteomics while assuming the interim role at the parent company.
Aditxt has also disclosed financial maneuvers aimed at strengthening its balance sheet. The company announced a $1.25 million private placement of senior unsecured promissory notes. These notes carry an annual interest rate of 10% and have a maturity date of September 30, 2026. Additionally, Aditxt is implementing a 1-for-27 reverse stock split, which became effective on May 18, 2026, following approval from stockholders.
Regulatory compliance remains a focus for the company. Aditxt announced that it has regained compliance with Nasdaq's continued listing standards, as confirmed by a letter from The Nasdaq Stock Market LLC. This compliance was based on the company's Annual Report, which indicated stockholders' equity of nearly $4 million. These developments reflect Aditxt's ongoing efforts to strengthen its financial and operational standing amidst the broader restructuring efforts.